Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Has reproduction · 73
FRMD8 inhibits tumor metastasis in BRCA1-associated TNBC by negatively regulating tmTNF-α.
PMID 40619383 · PMC12229025 · Cellular & molecular biology letters · 2025 · 8 claims · 8 setups
Low FRMD8 expression in BRCA1-mutant breast cancer cells significantly enhances metastatic potential to various organs
-
Full-text index only
Integrative bulk and single-cell transcriptomics link EZH2 to immunosuppressive programs and tumor-Treg crosstalk in castration-resistant prostate cancer.
PMID 41710887 · PMC12909565 · Frontiers in immunology · 2026 · 8 claims · 8 setups
Higher EZH2 expression is associated with adverse clinical outcomes in bulk PCa/CRPC cohorts
-
Has reproduction · 64
Characterizing Neutrophil Subtypes in Cancer Using scRNA Sequencing Demonstrates the Importance of IL1β/CXCR2 Axis in Generation of Metastasis-specific Neutrophils.
PMID 38358352 · PMC10903300 · Cancer research communications · 2024 · 8 claims · 7 setups
Two main neutrophil subtypes exist in primary tumors: an activated subtype sharing transcriptomic signatures with healthy neutrophils, and a tumor-specific subtype.
-
Full-text index only
The complement system contributes to the immunosuppressive microenvironment of uveal melanoma.
PMID 41803879 · PMC13130498 · Journal of translational medicine · 2026 · 8 claims · 8 setups
Primary UM (pUM) preferentially expresses early complement pathway components over terminal membrane attack complex elements, with early factors showing prognostic significance.
-
Full-text index only
Development and validation of an oxidative phosphorylation based prognostic model revealing tumor progression and immune microenvironment in lung adenocarcinoma.
PMID 41670771 · PMC12996521 · Discover oncology · 2026 · 8 claims · 8 setups
OXPHOS activity is significantly elevated in LUAD tumor tissue compared to adjacent normal tissue